RIX4414 (Rotarix™): A live attenuated human rotavirus vaccine;RIX4414 (Rotarix™): Uma vacina contra o rotavírus humano com vírus vivo atenuado

Jornal de Pediatria

Volumn 83, Issue 3, 2007, Pages 193-195

  Bernstein, David I ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIX 4414; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; LIVE VACCINE; RIX4414 VACCINE;

AGE DISTRIBUTION; ANTIBODY PRODUCTION; CLINICAL FEATURE; CLINICAL TRIAL; DEHYDRATION; DEVELOPED COUNTRY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GASTROINTESTINAL INFECTION; HUMAN; IMMUNIZATION; INTUSSUSCEPTION; ROTAVIRUS; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS TRANSMISSION; CHILD; GASTROENTERITIS; IMMUNOLOGY; NOTE; VIROLOGY;

CHILD; GASTROENTERITIS; HUMANS; ROTAVIRUS; ROTAVIRUS INFECTIONS; VACCINES, ATTENUATED;

EID: 34249995213     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/JPED.1632     Document Type: Editorial

References (17)

1. Institute of Medicine. Prospects for immunizing against rotavirus. New vaccine development: establishing priorities: diseases of importance in developing countries. v. 2. Washington, (DC): National Academy; 1986:303-318.
2. Parashar UD, Gibson CJ, Bresse JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis. 2006;12:304-6.
3. Glass RI, Parashar UD, Bresee JS, Turcios R, Fisher TK, Widdowson MA, et al. Rotavirus vaccines: current prospects and future challenges. Lancet. 2006;368:323-32.
4. Research priorities for diarrhoeal diseases vaccines: memorandum from a WHO meeting. Bull World Health Organ. 1991;69:667-76.
5. Kapikian AZ. Viral gastroenteritis. JAMA. 1993;269:627-30.
6. Staat MA, Azimi PH, Berke T, Roberts N, Bernstein DI, Ward RL, et al. Clinical presentations of rotavirus infection among hospitalized children. Pediatr Infect Dis J. 2002;21:221-7.
7. Murphy TV, Gargiullo PM, Massoudi MS, Nelson DB, Jumaan AO, Okoro CA, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med. 2001;344:564-72.
8. Peter G, Myers MG; National Vaccine Advisory Committee; National Vaccine Program Office. Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics. 2002;110:e67.
9. Clark HF, Offit PA, Plotkin SA, Heaton PM. The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants. Pediatr Infect Dis J. 2006;25:577-83.
10. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med; 2006;354:23-33.
11. Araújo EC, Clemens SC, Oliveira CS, Justino MC, Rubio P, Gabbay YB, et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy Brazilian infants. J Pediatr (Rio J). 2007;83:217-24.
12. Bernstein DI, Sander DS, Smith VE, Schiff GM, Ward RL. Protection from rotavirus reinfection: 2-year prospective study. J Infect Dis. 1991;164:277-83.
13. Bernstein DI, Smith VE, Sherwood JR, Schiff GM, Sander DS, DeFeudis D, et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine. 1998;16:381-7.
14. Bernstein DI, Sack DA, Rothstein E, Reisinger K, Smith VE, O'Sullivan D, et al. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet. 1999;354:287-90.
15. Bernstein DI, Sack DA, Reisinger K, Rothstein E, Ward RL. Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants. J Infect Dis. 2002;186:1487-9.
16. Bernstein DI. Live attenuated human rotavirus vaccine, Rotarix. Semin Pediatr Infect Dis. 2006;17:188-94.
17. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354:11-22.